EMEA-003225-PIP01-22 - paediatric investigation plan
tinlarebant
PIPHuman
Key facts
- Active Substance
- tinlarebant
- Therapeutic area
- Congenital, familial and genetic disorders
- Decision number
- P/0060/2024
- PIP number
- EMEA-003225-PIP01-22
- Pharmaceutical form(s)
- Tablet
- Age-appropriate oral formulation
- Condition(s) / indication(s)
- Treatment of Stargardt disease
- Route(s) of administration
- Oral use
- Contact for public enquiries
Belite Bio Inc.
E-mail: clinicaltrial@belitebio.com
Tel: +1 8586925980- Decision type
- P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
- Decision date